The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease by Harbord, Marcus et al.
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved.  
For permissions, please email: journals.permissions@oup.com
1
Journal of Crohn's and Colitis, 2016, 1–16
doi:10.1093/ecco-jcc/jjv213
ECCO Guidelines/Consensus Paper
ECCO Guidelines/Consensus Paper
The First European Evidence-based Consensus 
on Extra-intestinal Manifestations in 
Inflammatory Bowel Disease
Marcus Harbord,a,† Vito Annese,b Stephan R. Vavricka,c Matthieu Allez,d 
Manuel Barreiro-de Acosta,e Kirsten Muri Boberg,f Johan Burisch,g  
Martine De Vos,h Anne-Marie De Vries,i Andrew D. Dick,j Pascal Juillerat,k 
Tom H. Karlsen,l Ioannis Koutroubakis,m Peter L. Lakatos,n Tim Orchard,o 
Pavol Papay,p Tim Raine,q Max Reinshagen,r Diamant Thaci,s  
Herbert Tilg,t Franck Carbonnel;u,† for the European Crohn’s and  
Colitis Organisation [ECCO]
aDepartment of Gastroenterology, Chelsea and Westminster NHS Foundation Trust, London, UK  bDepartment 
of Emergency, University Hospital Careggi, Florence, Italy cDivision of Gastroenterology and Hepatology, 
Triemli Hospital, Zurich, Switzerland dDepartment of Gastroenterology, Hôpital Saint Louis, Sorbonne Paris-
Cité University, Paris, France eDepartment of Gastroenterology, University Hospital Santiago De Compostela, A 
Coruña, Spain fDivision of Cancer Medicine, Surgery and Transplantation, Norwegian PSC Research Center, Oslo 
University Hospital, Rikshospitalet, Oslo, Norway gGastro Unit, Hvidovre University Hospital, Hvidovre, and Danish 
Centre for eHealth & Epidemiology, North Zealand University Hospital, Copenhagen, Denmark hDepartment of 
Gastroenterology, University Hospital Ghent , Ghent, Belgium iDepartment of Gastroenterology and Hepatology, 
University Medical Center Rotterdam, Rotterdam, The Netherlands jAcademic Unit of Ophthalmology, School 
of Clinical Sciences, Bristol, and National Institute for Health Research, Moorfield’s Eye Hospital and UCL 
Institute of Ophthalmology, London, UK kClinic for Visceral Surgery and Medicine, University Hospital Bern, Bern, 
Switzerland lInstitute of Clinical Medicine, University of Oslo, Oslo, Norway mDepartment of Gastroenterology, 
University Hospital Heraklion, Heraklion, Greece nDepartment of Medicine I, Semmelweis University, Budapest, 
Hungary oImperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK pDepartment of Internal 
Medicine, Hartmannspital Vienna, Vienna, Austria qDepartment of Gastroenterology, Addenbrooke’s Hospital, 
Cambridge, UK rMedizinische Klinik I, Klinikum Braunschweig, Germany sComprehensive Center of Inflammation 
Medicine, University Hospital Schleswig Holstein, Lubeck, Germany tDepartment of Internal Medicine, University 
Hospital Innsbruck, Innsbruck, Austria uService de Gastroentérologie CHU de Bicêtre, Université Paris Sud, 
Paris, France
†These authors acted as convenors of the Consensus and contributed equally to this paper. 
Corresponding author: Marcus Harbord, Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London SW10 
9NH, UK. Tel: +44 203 315 1073; email: MarcusHarbord@me.com
Keywords:  ECCO; inflammatory bowel disease; extra-intestinal manifestation; Crohn’s disease; ulcerative colitis
1. Introduction
This is the first European Crohn’s and Colitis Organisation [ECCO] 
consensus guideline that addresses extra-intestinal manifestations 
[EIMs] in inflammatory bowel disease [IBD]. It has been drafted by 
21 ECCO members from 13 European countries. Although this is 
the first ECCO consensus guideline that primarily addresses EIMs, 
it is partly derived from, updates, and replaces previous ECCO 
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consensus advice on EIMs, contained within the consensus guide-
lines for Crohn’s disease1 [CD] and ulcerative colitis2 [UC]. The 
strategy to define consensus was similar to that previously described 
in other ECCO consensus guidelines [available at www.ecco-ibd.
eu]. Briefly, topics were selected by the ECCO guidelines committee 
[GuiCom]. ECCO members were selected to form working groups. 
Provisional ECCO Statements and supporting text were written fol-
lowing a comprehensive literature review, then refined following two 
voting rounds which included national representative participation 
by ECCO’s 35 member countries. The level of evidence was graded 
according to the Oxford Centre for Evidence-based Medicine [www.
cebm.net]. The ECCO Statements were finalised by the authors 
at a meeting in Vienna in October 2014 and represent consensus 
with agreement of at least 80% of participants. Complete consen-
sus [100% agreement] was reached for most statements. The sup-
porting text was then finalised under the direction of each working 
group leader [VA, SV, FC, MH] before being integrated by the two 
consensus leaders [MH, FC]. This consensus guideline is pictori-
ally represented within the freely available ECCO e-Guide [http://
www.e-guide.ecco-ibd.eu/].
Up to 50% of patients with inflammatory bowel disease [IBD] 
experience at least one extra-intestinal manifestation [EIM], which 
can present before IBD is diagnosed.34,5,6 EIMs adversely impact 
upon patients’ quality of life and some, such as primary scleros-
ing cholangitis [PSC] or venous thromboembolism [VTE], can be 
life-threatening. The probability of developing EIMs increases with 
disease duration and in patients who already have one EIM.7 EIMs 
are more common in CD than UC,7,8 particularly in patients with 
colonic CD; some EIMs, such as iritis/uveitis, are more common in 
women whereas PSC and ankylosing spondylitis are more common 
in males.3 Most EIMs run in parallel with intestinal disease activity,4 
with the exception of ankylosing spondylitis and uveitis and with 
uncertainty regarding PSC and pyoderma gangrenosum [PG].9 The 
management of complex EIMs should be discussed in a multidisci-
plinary team meeting.
2. Arthropathy and arthritis
2.1. Investigation and diagnostic criteria
Arthropathies associated with IBD belong to the SpA group of con-
ditions. According to the Assessment in Spondyloarthritis International 
Society [ASAS] classification of 2009,10 SpA are divided into axial and 
peripheral SpA, depending on the predominant symptoms. Diagnosis of 
axial SpA is based on magnetic resonance imaging [MRI] or radiographic 
features of sacroiliitis associated with clinical features of inflammatory low 
back pain. Radiological evidence of sacroiliitis is common in both UC and 
CD, occurring in 20–50 % of patients,11,12,13 but progressive AS with syn-
desmophytes occurs in only 1–10 % of patients.14,15,16 Early assessment 
using T1-weighted spin-echo [TISE], short tau inversion recovery [STIR], 
and fat-saturated T2-weighted sequences, are recommended for patients 
aged less than 40 years with inflammatory back pain lasting more than 
3  months, to identify non-radiographic sacroiliitis.17,18 Human leuko-
cyte antigen [HLA]-B27 is found in 25–75% of patients with IBD and 
AS11,19,20,21 but only in 7–15% of patients with isolated sacroiliitis. HLA-
B27 positive IBD patients seem to be at risk for the development of AS21 
but, due to a lower prevalence than in idiopathic AS, it is unreliable as a 
diagnostic test in IBD.22,23
The peripheral arthritis of IBD is an inflammatory arthropathy but, 
unlike psoriatic arthritis and other inflammatory arthropathies, it is 
generally non-erosive. The ASAS guidelines for peripheral SpA included 
only six patients with IBD,24 so the clinical classification of IBD-related 
peripheral arthropathies is usually based on a larger study of IBD 
patients.25 On the basis of articular involvement and natural history, 
two different types have been empirically identified. Type 1 is defined 
as joint pain with evidence of swelling or effusion affecting fewer than 
five joints, mainly the large weight-bearing joints of the lower limb. 
The symptoms are usually acute and self-limiting [less than 10 weeks] 
without permanent joint damage, and usually correlate with IBD flares. 
Type 2 affects more than five joints, has a symmetrical distribution, and 
predominantly affects the upper limbs. Symptoms persist for months 
or years, independent of IBD activity. Diagnosis is made on clinical 
grounds based on characteristic features of inflammation and exclu-
sion of other specific forms of arthritis. Imaging excludes deformity, 
in contrast to osteoarthritis, rheumatoid arthritis, and connective tis-
sue diseases. IBD-associated peripheral arthritis has to be differentiated 
from arthralgia [which may complicate corticosteroid withdrawal], 
osteonecrosis related to corticosteroids, and infliximab-related lupus-
like syndrome.26
Enthesopathies and dactylitis have been studied less extensively in 
IBD. Enthesitis describes inflammation at the insertion of a tendon to 
the bone leading to erosions and bone proliferation [spur formation]. 
Patients suffer pain, tenderness, and swelling. Dactylitis [sausage-like 
ECCO Statement 2A
Both peripheral and axial arthropathies occur in UC and 
CD, and belong to the spondyloarthritis [SpA] group of 
conditions (evidence level 2 [EL2]). They should be distin-
guished from arthralgia, which is more common. The prev-
alence of axial disease is equal between sexes and forms 
of IBD, but peripheral arthropathies are more common in 
CD [particularly affecting the colon] and in females [EL3]
ECCO Statement 2B
Diagnosis of axial SpA is based on the clinical feature of 
inflammatory low back pain associated with magnetic 
resonance imaging [MRI ]or radiographic features of sac-
roiliitis [EL 2]. Human leukocyte antigen B27 [HLA-B27] is 
associated with axial arthritis, but it has a lower preva-
lence than in idiopathic ankylosing spondylitis, making it 
unreliable as a diagnostic test in IBD [EL2]
ECCO Statement 2C
Radiological evidence of sacroiliitis occurs in 20–50% 
of patients with UC and CD, but progressive ankylosing 
spondylitis occurs in only 1–10% of patients [EL2]. MRI 
may identify early sacroiliitis in symptomatic patients 
with normal plain radiology [non-radiographic SpA] [EL2]
ECCO Statement 2D
Diagnosis of peripheral arthropathy and/or enthesitis 
associated with IBD is based on signs of inflammation and 
exclusion of other specific forms of arthritis [EL3]. Type I is 
an acute pauciarticular arthritis, affecting large joints, and 
is usually associated with active IBD. Type II is polyarticu-
lar, affecting a larger number of peripheral joints, and is 
independent of IBD activity [EL4]
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fingers or toes] is characteristic of SpA, with a prevalence of 2–4% in 
IBD.21,25
2.2. Natural history and pathogenesis
Peripheral arthritis in IBD is usually asymmetrical and oligoarticular, 
and more common in CD, particularly in those with colonic disease. 
Its onset may precede that of bowel symptoms, although it usually 
coincides with or presents after the appearance of IBD.27,28 Its preva-
lence in IBD ranges from 5% to 20% [5–14% in UC and 10–20% 
in CD].14,26,27 In general, the prognosis of peripheral arthritis is good, 
only becoming chronic and erosive in a minority of patients. The 
prognosis of axial involvement is less favourable and is related to 
the prognosis of AS, and not the progress of IBD. Classic AS is a 
progressive condition with structural damage and disability affecting 
patients’ quality of life. It is important to identify early non-radiolog-
ical axial SpA, to try prevent the progression to radiographic axial 
SpA that occurs in 10–20 % by 2 years in those with an elevated 
C-reactive protein [CRP] or with active inflammation on MRI.29
The importance of IBD in the pathogenesis of SpA is underscored 
by the finding that sacroiliitis and spondylitis occur in up to 20% 
of patients with IBD, whereas up to 70% of patients with AS or 
SpA have microscopic evidence of gut inflammation, although only 
7% develop CD.30 The association of HLA-B27 with AS is seen in 
IBD, but to a lesser degree than in idiopathic AS [≈70% vs 94%].31 
This may relate to the overlap between the genetics of AS and IBD. 
Genome-wide association studies [GWAS] and meta-analyses have 
discovered more than 160 loci for IBD susceptibility. Notably, in an 
extensive meta-analysis and validation in over 75 000 IBD cases and 
controls,32 8 of 11 identified loci for AS were shared by IBD with a 
13-fold enrichment above that expected. These are: IL23R, IL12B, 
STAT3, and PTGER4 linked to the TH17 pathway; CARD9 linked 
to the NFκB pathway; and ILR2 and ORMDDL3 linked to immune 
responses. These associations corroborate a common genetic back-
ground beyond the major histocompatibility complex [MHC].33
2.3. Treatment 
Recommendations for the treatment of IBD-related arthropathy are 
based on studies in SpA, predominantly AS. Prospective controlled trials 
in IBD have not been published; only small open-label trials or case 
reports are reported.34,35,36,37
Patients with axial SpA should be jointly managed with rheuma-
tologists because of the potential disabling disease course. Evidence 
supports the use of intensive physiotherapy and non-steroidal anti-
inflammatory drug [NSAIDs] in axial arthropathy, but long-term 
treatment with NSAIDs is best avoided in IBD.38 Although NSAIDs 
increase the risk for relapse,39,40 a larger cohort study including 426 
CD patients and 203 UC patients illustrated that short-term ther-
apy with low doses of NSAIDs was well tolerated41; use of high-
dose NSAIDs was associated with higher disease activity among 
those with Crohn’s colitis, but this was not reflected by a significant 
increase in disease flares. The use of COX-2 inhibitors such as etori-
coxib and celecoxib may be safer, with a lower risk of disease flare, 
than conventional NSAIDs.42,43 Methotrexate and thiopurines, in 
contrast, are of limited efficacy.44
Anti- tumour necrosis factor [TNF] is the preferred treatment in 
patients intolerant or refractory to NSAIDs.45 Conclusive data on the 
long-term effect of anti-TNF on radiographic progression are lacking, 
though recent data report less pronounced bone formation.46,47 Anti-TNF 
therapy may reduce progression of early non-radiological axial SpA,48,49 
although results of large prospective follow-up studies are required.
Effective treatment of underlying gut inflammation is often suf-
ficient to treat peripheral arthritis. However, there is general sup-
port for the use of short-term systemic corticosteroids, NSAIDs, 
and local steroid injections for symptomatic relief.50 Although sul-
fasalazine and methotrexate are ineffective or only marginally effec-
tive in ankylosing spondylitis,44 a 2014 Cochrane review reported 
effectiveness of sulfasalazine in patients with peripheral disease, and 
recommended the drug for patients with short disease duration and 
increased erythrocyte sedimentation rate [ESR],51 although a review 
in 2012 concluded that sulfasalazine was not superior to placebo.52 
A recent study supports the current recommendation that sulfasala-
zine be an optional treatment in SpA patients with peripheral dis-
ease, although overall responses are modest. Initial treatment with 
sulfasalazine does not seem to impair later anti-TNF responses.53 
Sulfasalazine can be effective in large-joint arthropathy.54,55 Anti-
TNF therapy has been shown to be effective in small case series35 in 
patients with persistent disease impacting on quality of life.
Arthralgia [joint pain without inflammation] is common in IBD 
and may be associated with the introduction of thiopurines or the 
withdrawal of corticosteroids. Arthralgia associated with azathio-
prine is often associated with myalgia and usually appears during 
the first 3 months of therapy. Switching to mercaptopurine is usually 
effective.56
3. Metabolic bone disease
3.1. Investigations and diagnostic criteria
Low bone mass and osteoporosis are common in male and female 
patients with IBD [20–50%]. Contributing factors include chronic inflam-
mation, corticosteroid treatment, extensive small-bowel disease or resec-
tion, age, smoking, low physical activity, and nutritional deficiencies.57
ECCO Statement 2E
Patients with axial SpA should be jointly managed with 
rheumatologists. Intensive physiotherapy and short-
term non-steroidal anti-inflammatory drugs [NSAIDs] are 
effective [EL 3], but long-term treatment with NSAIDs is 
not recommended [EL2]. Sulfasalazine [EL2] and metho-
trexate [EL2] are of limited efficacy; therefore early anti-
tumour necrosis factor [TNF] is the preferred treatment 
for those intolerant or refractory to NSAIDs [EL2]
ECCO Statement 2F
Treatment of underlying gut inflammation is often suffi-
cient to treat peripheral arthritis [EL2], although short-term 
NSAIDs or local steroid injection provide symptomatic 
relief [EL4]. Short-term oral corticosteroids are effective 
[EL 3], but should be discontinued as soon as practicable. 
In persistent arthritis, sulfasalazine [EL2] and methotrex-
ate [EL4] may have a role. Anti-TNF therapy is appropriate 
and effective in resistant cases [EL2]
ECCO Statement 3A
Diagnosis of osteoporosis in adults is best made from a 
T-score < −2.5 on radiographic bone densitometry [EL1]. 
Osteoporosis is a risk factor for fracture and identifies 
patients who should receive treatment [EL2]
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The diagnosis of osteoporosis in adults is based on assessment of 
bone mineral density [BMD] by dual-energy X-ray absorptiometry 
[DXA]. Osteoporosis is defined as a BMD value at least 2.5 stand-
ard deviations lower than the mean BMD for young healthy adults 
[T-score ≤ −2.5].58 In children, the relationship between BMD and 
fracture risk is not well established and reference to the Z-score has 
been recommended. A Z-score < −2 should be reported as ‘below 
expected range for age’ and the need for treatment interpreted in the 
context of fracture risk factors [e.g. low weight, previous fracture, 
medication, IBD activity].59
Incidentally performed abdominal computed tomography [CT] 
is able to measure lumbar spine BMD accurately and so can be 
reviewed to exclude osteoporosis,60,61 although multi-detector CT 
and high-resolution peripheral quantitative CT, quantitative ultra-
sonography, MRI, and MR spectroscopy are research applications 
and not recommended as elective screening techniques.62
Screening recommendations for IBD patients do not differ from 
those for the general population and are based on risk factors such 
as postmenopausal state, ongoing corticosteroid treatment, cumula-
tive corticosteroid use > 3 months, history of low-trauma fracture, 
and age.63,64 Annual DXA scans have been recommended in those 
receiving long-term corticosteroids, especially in the context of risk 
factors, when the T-score approaches the threshold for treatment 
with bisphosphonates [T < −1.5].65 Osteoporosis identifies patients 
at above average risk for fractures of the spine and peripheral long 
bones; they should receive treatment, since the fracture risk increases 
about 2-fold for each standard deviation decline in BMD below the 
population mean.66,67 Vertebral fractures have been documented in 
patients with both reduced and normal bone density, challenging 
the concept that osteoporosis is the main risk factor for vertebral 
fractures in young patients with IBD.68,6,970 No linear association 
between lumbar bone density and spontaneous fracture risk exists. 
The strongest predictor of future fracture is a previous vertebral 
fracture.
3.2. Natural history and pathogenesis
When measured by DXA, bone density of the lumbar spine is 
significantly reduced in the majority of patients with IBD, who 
are predominantly young patients aged between 20 and 40 years; 
40–50% of all patients have osteopenia, with a T-score < −1 
and > −2.5. Osteoporosis has been reported in 5–37% of IBD 
patients.71,72,73,7475
A significant proportion of IBD patients can normalise their bone 
density after 3 years in stable remission.76 Only a few studies have 
investigated longitudinal changes in BMD prospectively. Treatment 
with anti-TNF often improves bone density.77 Population-based 
studies have shown that factors predicting changes in BMD are simi-
lar in IBD to those seen in the general population.21,22 The relative 
importance of each risk factor remains to be established.
Recently there has been increasing recognition of the immuno-
logical role of vitamin D.78,79,80,8182 Deficiency can be a consequence 
of IBD.81,82,83 Vitamin D deficiency is common in newly diagnosed 
IBD patients, and so may contribute to increased risk of IBD.84 
A recent cohort study suggests a possible role for vitamin D in IBD 
pathogenesis: women living in southern latitudes had a lower risk of 
CD (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.3–0.7) 
and UC [HR 0.62, 95% CI 0.4–0.9] than those living in northern 
latitudes.85 These findings are consistent with previous data suggest-
ing a north-south gradient in disease incidence,86 mimicking expo-
sure to ultraviolet light, a major determinant of vitamin D status.87,88
3.3. Treatment
Treatment should be considered in patients with low BMD and/or 
additional risk factors. Fracture prediction tools such as FRAX, which 
calculates fracture risk in the absence of a direct measurement of BMD, 
may be useful in determining who requires treatment,89,90 although FRAX 
has not been validated in IBD populations nor in individuals aged < 
50 years. Exposure to factors known to increase bone loss and/or fracture 
should be limited. Measures like weight-bearing or resistive exercises, 
smoking and excess alcohol cessation, and maintaining adequate dietary 
calcium [1 g/d]91 from diet and/or supplements should be implemented.
Vitamin D should be maintained in the recommended range; this 
usually requires supplements at a dose of ~ 1000 IU [25  µg] daily, 
or higher dose if known vitamin D deficiency. Supplemental calcium 
should be given only if dietary calcium is < 800 mg/d. Treatment with 
calcium 500–1000 mg/day and vitamin D [800–1000 IU/day] increases 
bone density in patients with IBD.57 A recent large study in CD showed 
that tight control of disease activity and supplementation of calcium and 
vitamin D were associated with a median annual increase in BMD of 
0.76% over 4 years.92 The value of calcium and vitamin D in preventing 
fractures has not been demonstrated in patients with IBD, although effi-
cacious in postmenopausal or steroid-induced osteoporosis.93 Vitamin 
D deficiency is common in patients with IBD and should be corrected 
as necessary.94 Patients receiving systemic steroid therapy should receive 
calcium and vitamin D for prophylaxis.
Meta-analysis showed that bisphosphonates are effective for the 
treatment of low BMD in IBD and reduce the risk of vertebral but 
not non-vertebral fractures95 and can therefore be recommended 
for fracture prevention in IBD patients. Due to the heterogeneity 
of studies, a general recommendation for fracture prevention with 
bisphosphonates is not feasible in young, premenopausal women 
or young men. Bisphosphonate-related osteonecrosis of the jaw is 
a rare side effect [< 1%] and should be considered in patients with 
poor dental status or insufficient dental hygiene. In these patients, 
a dental examination including radiographs before therapy might 
ECCO Statement 3B
Weight-bearing exercise [EL2], stopping smoking [EL3], 
and maintaining adequate dietary calcium [1 g/day] [EL2] 
are beneficial in preventing bone loss. Patients receiving 
systemic steroid therapy should receive calcium and vita-
min D for prophylaxis for the duration of treatment [EL5]
ECCO Statement 3C
Osteopenia is a prognostic marker for osteoporosis [EL3], 
therefore calcium and vitamin D are recommended if the 
T score is less than -1.5 [EL4]. In these patients, a history 
of pre-existing fracture should prompt consideration for 
more intensive treatment [EL4]
ECCO Statement 3D
Management of underlying disease activity is important, 
particularly in the young whereas, in postmenopausal 
women or those with previous spontaneous fractures, 
regular use of bisphosphonates and other therapies can 
prevent further bone loss [EL2]
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be appropriate.96 Other emergent side effects are atypical femoral 
fracture and oesophagitis. Rheumatologists have virtually stopped 
using calcitonin or raloxifene as these are associated with only small 
increases in bone density and small reductions in vertebral fracture 
risk. There is no evidence that they reduce hip or other peripheral 
fractures.
The evidence for treatment and prevention of osteoporosis in 
young patients is limited. All patients with persistently active dis-
ease should be treated according to guidelines with immunosup-
pressive therapy [thiopurines, anti-integrins, anti-TNF] to avoid 
prolonged steroid treatment and inflammatory activity, in order to 
prevent bone loss.97 Newer drugs like teriparatide, strontium rane-
late, or denosumab should be prospectively studied in patients with 
IBD before their use can be recommended. Recent data showed an 
increased cardiovascular risk for patients treated with strontium 
ranelate.98 Patients with more severe osteoporosis should be referred 
to a specialist.
4. Eye disease
4.1. Investigation and diagnostic criteria
Anterior uveitis and episcleritis are the most common ocular mani-
festations of IBD. Some ocular manifestations in IBD can be secondary to 
treatment and/or effects of the intestinal disease itself. The classification 
of uveitis has been set out in the Standardization of Uveitis Nomenclature 
[SUN] guidelines99 [Table 1].
The most commonly reported ocular manifestations are dry eye, 
blepharitis, episcleritis, or anterior uveitis. Scleritis and intermediate 
or posterior uveitis [which are more likely to be sight-threatening] are 
much rarer, occurring in less than 1%, but left untreated may pro-
gress to permanent visual deficits. Reports of posterior uveitis include 
a series of 13 cases exhibiting a spectrum of features from choroiditis 
to retrobulbar neuritis.100 Whereas episcleritis tends to reflect disease 
activity in the bowel and other extra-intestinal sites, uveitis can be 
independent of bowel symptoms and other EIMs and may precede the 
onset of bowel symptoms.101 Other rare causes of ocular involvement 
with devastating consequences include vascular occlusion potentially 
secondary to vasculitis [including central retinal artery occlusion],102 
anterior ischaemic optic neuropathy,103 and orbital inflammation.
Episcleritis may be relatively painless, presenting with hyperae-
mic sclera and conjunctiva, and itching and burning may occur,104 as 
opposed to scleritis which is often very painful. Uveitis is less com-
mon but has potentially more severe consequences. When related to 
CD, uveitis is frequently bilateral, insidious in onset, and longlast-
ing,101,104 although characteristic acute anterior uveitis with sud-
den onset may occur. Patients complain of a variety of symptoms 
including the classical features of uveitis: eye pain, blurred vision, 
photophobia, and headache. The possibility of progression to loss 
of vision should prompt urgent referral to an ophthalmologist with 
expertise in the management of ocular inflammation, and the use 
of immunomodulatory and biological agents. Slit-lamp examination 
will confirm the diagnosis and permit the differentiation between 
anterior and posterior uveitis.
Mild pain associated with hyperaemia of the conjunctiva and 
episclera, without visual changes, often allows episcleritis to be dif-
ferentiated from scleritis. Visual disturbance, photophobia, mod-
erate to severe pain, or other ocular involvement should prompt 
ophthalmic referral for examination using a slit-lamp to assess for 
the presence of inflammatory cells and/or scleritis.
For uveitis, both the SUN guidelines99 and those of the 
International Uveitis Study Group [IUSG]105 are useful in disease 
classification. Severity assessment may also be useful in episcleritis 
and scleritis.106
4.2. Natural history and pathogenesis
Reports of the incidence of ocular manifestations range from 4–12% 
of IBD cases although in some cohorts this rises to 29%.107 None of 
these percentages is population based,and they tend to be limited to 
small numbers of patients studied in tertiary centres—hence are proba-
bly overestimates. One community study [only surveying 112 individu-
als of whom only 88 had IBD] showed that patients with IBD are more 
likely to complain of ocular symptoms compared with controls.108
Ocular [episcleritis and scleritis] and intraocular inflammatory 
disease [uveitis] as EIMs of IBD represent diverse pathologies, asso-
ciated with activation and infiltration of both innate and adaptive 
immune cells into the tissue or intraocular environment. In severe 
cases, this may be associated with scleritis with fibrinoid necrosis 
and vasculitis. Genetic associations supporting innate activation in 
uveitis include association with NOD2 mutations and MICA on 
MHC class I and are supported by animal models.109
4.3. Treatment
Once a firm diagnosis is established, the treatment of most ocular 
symptoms is straightforward. Dry eyes may be treated with topi-
cal lubricants. Episcleritis responds following management of the 
underlying bowel disease, and to the addition of topical NSAIDs 
[for analgesia] and glucocorticoids.104,110 Anterior uveitis should be 
treated with topical corticosteroids and cycloplegics. For refractory 
uveitis and other rarer manifestations, the level of evidence remains 
low, with the evidence for efficacy of therapies being higher in 
patients with uveitis but without IBD. Successful use of topical and 
systemic corticosteroids, immunomodulator therapy, or biologicals 
Table 1. Classification of uveitis.
Anterior uveitis: Primary site of inflammation: anterior chamber
Intermediate uveitis: Primary site of inflammation: vitreous
Posterior uveitis: Primary site of inflammation: retina or choroid
Pan-uveitis: Primary site of inflammation: anterior chamber, vitreous, 
retina or choroid
ECCO Statement 4A
Simple episcleritis does not require referral to an ophthal-
mologist. This should be differentiated from uveitis and 
scleritis, based upon the absence of moderate-severe eye 
pain, photophobia, blurring, and diminished vision. When 
this is not possible, or in patients with possible sight-
threatening ocular manifestations [scleritis and uveitis], 
patients should be treated by an ophthalmologist with 
expertise in ocular inflammatory disease [EL5]
ECCO Statement 4B
Episcleritis may self-resolve. Topical or systemic NSAIDs 
or topical corticosteroids can be used for symptomatic 
treatment [EL4]. Treatment for scleritis or uveitis should 
be guided by an ophthalmologist, and includes topical or 
systemic corticosteroids, conventional immunosuppres-
sants, and anti-TNF agents [EL4]
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have all been reported, mainly from non-controlled retrospective 
cohorts [level 3 or 4 evidence]. Expert opinion favours the use of 
immunomodulators and biologicals in posterior uveitis and scleri-
tis,111,112,113 but is based upon evidence taken from the treatment of 
uveitis, where only a minority had IBD. Azathioprine, methotrexate, 
infliximab, and adalimumab have each been reported to be valuable 
in resistant cases.
5. Oral, aural and nasal disease
Oral CD includes deep ulcerations, pseudopolyps, and labial or buc-
cal swelling. It is often associated with perineal disease and has a 
protracted course.114 Metastatic CD involvement of nasal mucosa, 
and aseptic nasal septal abscess associated with UC, have been 
reported.115,116,117 Sensorineural hearing loss has been described in 
association with IBD, particularly in patients with UC,118 and may be 
due to inner-ear obliteration, demonstrated by inner-ear T2-weighted 
MRI.119 Cogan’s syndrome is a rare autoimmune disease that results 
in non-syphilitic keratitis and vestibular-auditory symptoms that 
often lead to deafness. It can be associated with IBD.120
6. Skin disease
6.1. Erythema nodosum
6.1.1. Investigation and diagnostic criteria
EN is readily recognised and characterised by raised, tender, red, or 
violet subcutaneous nodules, of 1–5cm in diameter. It commonly 
affects the extensor surface of the extremities, particularly the ante-
rior tibial areas, and usually occurs at times of IBD activity. EN often 
presents in association with systemic symptoms including arthralgia 
and fatigue. The differential diagnosis includes metastatic CD, which 
may appear at any site as solitary or multiple nodules, plaques, 
ulcers, or violaceous perifollicular papules, with non-caseating gran-
ulomas present histologically.121 EN can also involve the trunk or 
upper extremities.9 A firm clinical diagnosis can normally be made 
and biopsy is not usually appropriate. If performed, the histology 
reveals a non-specific focal panniculits.122,123
6.1.2. Natural history and pathogenesis
The prevalence of EN in IBD ranges from 4.2% to 7.5%,124,125,126 
higher in CD than UC4,125 and more common among female IBD 
patients.124 The pathogenesis of EN is not well understood. Some 
data suggest that it could be a type IV hypersensitivity reaction, 
because the trigger can be identified in almost 40% of patients.127
6.1.3. Treatment
EN is normally associated with IBD flares, but not always with 
severity.123 Because it is closely related to disease activity, treatment is 
based on that of the underlying IBD. Systemic corticosteroids may be 
required in severe cases. In resistant cases or when there are frequent 
relapses, immunomodulation with azathioprine, infliximab, or adali-
mumab may be used.128,129
6.2. Pyoderma gangrenosum
6.2.1. Investigation and diagnostic criteria
Pyoderma gangrenosum [PG] can occur anywhere on the body, 
including the genitalia, but the commonest sites are the shins and 
adjacent to stomas.9 Initially PG takes the form of single or multi-
ple erythematous papules or pustules, but subsequent necrosis of the 
dermis leads to the development of deep excavating ulcerations that 
contain purulent material that is sterile on culture unless secondary 
wound infection has occurred. PG is characterised by the appear-
ance of a skin pustule that quickly becomes a burrowing ulcer with 
violaceous edges, with a size between 2 cm and 20 cm in diameter. It 
can expose tendons, muscles, and deep tissues. PG is usually diag-
nosed clinically, based on the characteristic appearance of the lesions 
following exclusion of other possible skin diseases [e.g. ecthyma, 
necrotising vasculitis, necrobiosis lipoidica, arterial or venous insuf-
ficiency ulceration]. Since PG is a diagnosis of exclusion, it can be 
misdiagnosed in a substantial percentage of cases.130 In some cases 
a biopsy from the periphery of the lesion can help; findings in PG 
are non-specific, but biopsy can be helpful to exclude other skin 
disorders.
6.2.2. Natural history and pathogenesis
In recent publications, 0.6–2.1% of UC patients developed PG, a 
higher frequency than that observed in CD.124,125,131,132 The patho-
physiology is unknown, but PG has been hypothesised to involve 
abnormal neutrophil function and impaired cellular immunity.133 
Lesions are often preceded by trauma [pathergy].134 Controversy 
exists regarding the correlation between PG and IBD activity, as it 
may parallel IBD activity or run an independent course. PG has a 
tendency to recur following successful treatment in more than 25% 
of cases, often in the same place as the initial episode.124
6.2.3. Treatment
The therapeutic goal should be rapid healing, as it can be a debili-
tating skin disorder. There is no evidence that the efficacy of treatment 
strategies for PG differs between IBD and non-IBD patients.
Immunosuppression is the mainstay of treatment. Traditionally 
the most commonly used drugs were systemic corticosteroids and 
ciclosporin. Corticosteroids were considered first-line treatment, 
with oral ciclosporin and oral or intravenous tacrolimus reserved 
for refractory cases.135,136,137,138 Infliximab has, however, changed 
the management of PG in patients with UC. Its effectiveness was 
first reported in small case studies.139 The largest study on the 
treatment of PG with infliximab was a multicentre, randomised, 
placebo-controlled trial of 30 patients, including 19 patients with 
IBD.140 Infliximab 5 mg/kg or placebo was given at Week 0. At Week 
2 [the primary endpoint], significantly more patients in the inflixi-
mab group had improved compared with placebo [46% vs 6%, 
p = 0.025]. Thereafter, subjects in both arms were offered open-label 
infliximab. Overall, 29 patients received infliximab with the major-
ity demonstrating improvement [response 69%, remission 31% at 
ECCO Statement 6A
Diagnosis of erythema nodosum [EN] is made on clinical 
grounds. In atypical cases a skin biopsy might be helpful 
[EL3]. Treatment is usually based on that of the underlying 
IBD. Systemic corticosteroids are required in severe cases 
[EL4]. Relapsing and resistant forms can be treated with 
immunomodulators or anti-TNF [EL4]
ECCO Statement 6B
Pyoderma gangrenosum [PG] can be treated with sys-
temic corticosteroids, infliximab [EL1b] or adalimumab 
[EL3b], or topical or oral calcineurin inhibitors [EL4]
6 M. Harbord et al.
 by guest on February 17, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
Week 6]. The response rate was over 90% with short duration of 
PG [< 12 weeks], otherwise less than 50%. In a recent Spanish series 
of 67 IBD patients with PG, 46% needed anti-TNF treatment, with 
response close to 90%.141 As yet no trial has compared the efficacy 
of different immunosuppressive drugs. Infliximab should be consid-
ered if a rapid response to corticosteroids cannot be achieved. Case 
series have demonstrated the efficacy of adalimumab in the treat-
ment of PG.142,143,144 In patients with peristomal PG, closure of the 
stoma might lead to resolution of the PG lesions.145 The use of topi-
cal calcineurin inhibitors [pimecrolimus or tacrolimus] is an alter-
native, but the advice of a dermatologist should be sought. Daily 
wound care should be performed in collaboration with a wound-
care specialist.
6.3. Sweet syndrome [acute febrile neutrophilic 
dermatosis]
6.3.1. Investigation and diagnostic criteria
Sweet’s syndrome is part of the group of acute neutrophilic derma-
toses that includes PG, but can be distinguished by its appearance, 
distribution, and histological features. It is characterised by tender, 
red, inflammatory nodules or papules, usually affecting the upper 
limbs, face or neck.9,146 Fever can be present. It can be preceded 
by trauma [pathergy]. It has only been recognised as an IBD EIM 
recently.147,148 It is more common in women and in patients with 
colonic involvement or other EIMs. The rash is mostly associated 
with active disease.
6.3.2. Natural history and pathogenesis
Accurate data about incidence or prevalence are lacking. The patho-
genesis remains unclear, although several potential mechanisms have 
been suggested, such as a type III hypersensitivity, T-lymphocyte dys-
function, or an association with histocompatibility antigens.149 There 
are various associations, including para-inflammatory, drug-induced, 
pregnancy-related, and para-neoplastic disease.
6.3.3. Treatment
Systemic corticosteroids have been reported to be effective; immunosup-
pressants should be considered in resistant or highly relapsing cases.150
6.4. Anti-TNF induced skin inflammation
Immunomodulators and anti-TNF may induce cutaneous side 
effects, such as infection, malignancy, allergic reactions, and para-
doxical inflammation [see Table 2].
6.4.1. Investigation and diagnostic criteria
Several centres have reported the development of psoriatic and 
eczematous lesions in patients with CD and UC receiving anti-TNF 
therapy, an observation which does not seem to relate to the age of 
the patient or the duration of treatment.151,152 Psoriasiform eczema, 
eczema, and xerosis were the most commonly observed type of skin 
lesions. Case reports have been described, and controlled case series 
have been published.151,153
6.4.2. Natural history and pathogenesis
Skin lesions are reported in approximately 22% of patients treated 
with anti-TNF. Rahier et  al. assessed clinical characteristics, risk 
factors, and outcomes of skin disease in patients with IBD that 
presented with psoriatic and eczematous lesions induced by anti-
TNF.153 A total of 85 patients developed psoriatic [62 patients] and 
eczematous lesions [23 lesions]. Locations of eczematous lesions 
varied, whereas scalp and flexural varieties were mostly psoriatic. 
Skin lesions were not associated with IBD activity, but were more 
frequent among females and occurred with any type of anti-TNF 
agent [infliximab, adalimumab, or certolizumab]. Anti-neutrophilic 
antibodies were positively associated with skin paradoxical inflam-
mation.154 A role for T helper 17 and interferon-γ-secreting T helper 
1 cells, and IFN-α-expressing cells, has been described.155
6.4.3. Treatment
All cases should be managed together with the advice of a derma-
tologist. Topical therapy with corticosteroids, keratolytics [salicylic acid, 
urea], emollients, vitamin D analogues, and ultraviolet therapy [UVA or 
narrow-band UVB] result in partial or total remission in almost 50% 
of patients. Patients with psoriatic lesions that did not improve with 
topical therapy and who switched anti-TNF therapies occasionally devel-
oped recurrent lesions, suggesting a class effect. Ustekinumab has been 
reported to be useful in the treatment of the paradoxical effects of anti-
TNF therapy.155,156 However, recent reports have also emerged of pus-
tular psoriasis attributed to treatment with ustekinumab.157 The largest 
case series, however, is derived from the rheumatology literature, and the 
treatment is mainly based on expert opinion.158,159
7. Hepato-pancreato-biliary disease
7.1. Primary sclerosing cholangitis
7.1.1. Investigation and diagnostic criteria
Up to 30% of patients with IBD have altered biochemical liver tests.160 
PSC, drug-induced liver injury [DILI], and liver disease independent 
of IBD should be considered.161 PSC is the most common liver disease 
specific to IBD,162 and may affect up to 4–5% of patients in some geo-
graphical areas.163,164 Biliary strictures have been observed in IBD patients 
with normal liver function tests.165 In populations of Northern European 
descent, 70–80% of patients with PSC have concomitant IBD.162 
According to standard clinical, endoscopic and histological criteria, IBD 
in PSC is mainly classified as UC and less frequently as Crohn´s disease.166
Causes of secondary sclerosing cholangitis167 such as infection, 
immunodeficiency, ischaemia, pancreatic disease, or immunoglobu-
lin [Ig]G4-related conditions have to be excluded.168 Secondary scle-
rosing cholangitis has similar histopathological and/or radiological 
features, but usually in the absence of IBD.169
Symptoms of PSC include malaise, pruritus, fever, chills, night 
sweats, and right upper abdominal quadrant pain. Symptoms are 
intermittent and may be confounded by those of underlying IBD. In 
patients with IBD, a high clinical awareness for PSC is needed as this 
disease commonly presents asymptomatically.
In patients with cholestasis in whom secondary causes of scleros-
ing cholangitis have been excluded, a diagnosis of PSC can be made 
if magnetic resonance cholangiography [MRC] shows typical find-
ings.170,171,172,173,174 Although common practice at some centres, it has not 
been demonstrated that endoscopic retrograde cholangioscopy [ERC] is 
of added benefit to establish a diagnosis of PSC when the result of MRC 
is unclear and clinical suspicion of PSC is high. The ECCO consensus 
ECCO Statement 6C
Anti-TNF treatment can induce paradoxical inflammation 
of the skin [EL3], which is a drug-class effect and is usually 
reversible upon drug cessation. Referral to a dermatologist 
is recommended. Most cases are controlled with topical 
treatment and anti-TNF can usually be maintained [EL3]
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group suggests that ERC should be restricted to cases where interven-
tion is anticipated [e.g. stricture dilatation] and/or brush cytology speci-
men sampling is indicated. In patients with PSC, rectal indomethacin 
should always be considered as prophylaxis against post-ERCP (endo-
scopic retrograde cholangio-pancreatography) pancreatitis.173
In about 510% of patients, MRC is normal despite histological 
changes compatible with PSC. This patient group is now recognised as 
a disease variant called ‘small-duct PSC’,175 which is associated with a 
better prognosis.176 Histological changes of PSC are typically patchy and 
liver histology may be normal.177 In consequence, a liver biopsy is only 
warranted in patients showing biochemical and serological features of 
autoimmune hepatitis [AIH] or if small-duct PSC is suspected.172,178
Increased serum alkaline phosphatase [ALP] should raise the sus-
picion of accompanying PSC in an IBD patient, although values are 
normal in 10% of PSC patients.179 Serum aminotransferase levels 
[ALT, AST] are usually below 300 IU/l. Hypergammaglobulinaemia is 
observed in approximately 30% of PSC patients and should raise the 
prospect of AIH, which is found in up to 10% of PSC patients.180,181 
If concomitant features of AIH are suspected, serum autoantibodies 
[ANA, SMA, LKM etc] should be analysed, but have a low specific-
ity. Atypical perinuclear antineutrophil cytoplasmic antibodies are 
observed in 30–80% of PSC individuals, but are also found in AIH and 
IBD patients without PSC.182 IgG4-associated sclerosing cholangitis 
must be considered if serum IgG4 is elevated. A  diagnosis of IgG4-
associated sclerosing cholangitis is made according to the amended 
HISORt [histology, imaging, serology, other organ involvement, and 
response to therapy] criteria,183 and is classified as secondary sclerosing 
cholangitis in recent guidelines.170,184 Slightly elevated levels of serum 
IgG4 [up to 5 g/l] may be detected in PSC patients not fulfilling the 
criteria for IgG4-associated sclerosing cholangitis. These patients may 
exhibit a more severe disease course177 but specific management recom-
mendations are lacking.
7.1.2. Natural history and pathogenesis
The presence of PSC in an IBD patient dramatically affects progno-
sis. It is however important to acknowledge that median survival 
without liver transplantation reported from tertiary referral cen-
tres [10–12 years] is lower than that of population-based studies [> 
20 years].178 The use of clinical models [eg the Mayo risk score]185 for 
predicting outcome at the individual level is not recommended, and 
there is a need for research in determining prognosis and treatment 
response in PSC.186
Complications of PSC include cholestasis, cholangitis, cholecys-
tolithiasis, cholangiocarcinoma, colorectal carcinoma, osteoporosis, 
vitamin deficiency, and steatorrhoea. PSC may be associated with 
autoimmune diseases such as autoimmune thyroid disease, type 1 
diabetes, and coeliac disease.
PSC often leads to fibrosis and stricture development in the intra- 
and extra-hepatic biliary tree, mainly affecting medium and large bile 
Table 2. Dermatological drug adverse events.
Drug Adverse events Prevalence/comments
Thiopurines Skin and soft tissue infection
Non-melanoma skin cancer
Drug hypersensitivity
Shingles
Frequently cellulitis
Patient education, sun protection, and routine annual 
skin check important
Prevalence up to 10%377
Patients aged > 60 years treated in combination with 
systemic corticosteroids are at higher risk 378,379
Anti TNF Skin reactions
Drug-induced lupus erythematosus [DILE]
Skin and soft-tissue infection
Melanoma
Paradoxical skin reactions:
eczema-like, psoriasis-like
Subcutaneous injection site reaction and delayed infu-
sion reaction 380
Rare; no class effect 381
Cellulitis, erysipelas,
abscess [0.1% to 7%] 382,383
Slight increased risk 382,383,384
Psoriasis: pustular phenotype [commonly palms and 
soles]; eczema: atopic diathesis 385,386
Sulfasalazine Exfoliative dermatitis, StevensJohnson syndrome, and toxic epidermal 
necrolysis
Rare but serious skin reactions, some fatal; discontinue 
drug if skin or mucosal lesion387
Methotrexate Alopecia
Generalised skin rash
Oral and intertriginous lesions
 < 10%; more common long term
Less frequent than reported
Rare; consider drug over-dosage [daily instead of 
weekly]388
Vedolizumab Infusion-related and hypersensitivity reactions
Rash, pruritus, eczema,
acne
Requires previous antihistamine, hydrocortisone. and/ 
or paracetamol389
ECCO Statement 7A
High-quality MRC is recommended for an unexplained 
persistent or fluctuating biochemical cholestatic pattern, 
independent of symptoms of cholestasis [EL1]. Secondary 
sclerosing cholangitis should be excluded when diagnos-
ing large-duct PSC
ECCO Statement 7B
If high-quality MRC is normal in a patient with IBD and 
suspected PSC, a liver biopsy should be considered to 
diagnose small-duct PSC [EL2]
ECCO Statement 7C
A liver biopsy is recommended in PSC patients with fea-
tures of AIH [eg raised transaminases, high serum IgG, rel-
evant autoantibodies] [EL1]. High serum concentrations of 
IgG4 and/or an elevated IgG4/IgG1 ratio should prompt con-
sideration of IgG4-associated sclerosing cholangitis [EL4]
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ducts.166 Progressive inflammation ultimately destroys the bile ducts, 
resulting in end-stage liver disease, and associates with an increased 
risk of cholangiocarcinoma.187 Patients with concurrent IBD have a 
significantly higher rate of colorectal carcinoma compared with IBD 
patients without PSC or normal controls.188,189
Off patients with PSC and IBD, 55–95% present with extensive 
colitis. Backwash ileitis is reported in 20–51%, rectal sparing in 
18–65%, and 10–15% develop colorectal carcinoma.184,190192,193,193 
These features clearly suggest that although PSC is commonly associ-
ated with UC, PSC-associated IBD has specific features. For example, 
disease severity is often mild or quiescent,194 without the typical ‘dis-
tal-to-proximal’ distribution as right-sided inflammation dominates 
including ileal inflammation. This is paralleled by the right-sided 
dominance of colorectal carcinoma.195,196 This cannot be explained 
currently by genetic findings. It suggests that PSC-associated IBD has 
a unique phenotype that may require separate classification.163,190
PSC has a strong hereditary component. Early studies showed 
that PSC is associated with prototypical HLA, as in many other auto-
immune diseases. Recent genome-wide association studies [GWAS] 
have identified new loci. The first GWAS study identified important 
associations in MST1 and BCL2L11.197 Interestingly, MST1 has been 
linked to IBD pathogenesis in contrast to BCL2L11, which is mainly 
involved in apoptotic processes. IL-2, CARD9, and REL are further 
susceptibility loci in PSC; they all play a role in innate and adaptive 
immunity.198 The largest genetic study was reported in 2013.199 Here, 
the authors investigated 3789 PSC cases of European ancestry using 
the immunochip and identified 12 genome-wide significant associa-
tions outside the HLA complex, increasing the number of known PSC 
risk loci to 16. Six of these 12 loci showed a much stronger association 
with PSC than with IBD, suggesting the presence of genetically deter-
mined disease processes in PSC that are distinct from those of IBD.
7.1.3 Treatment
Currently, the evidence for medical treatment in PSC is in turn based 
on little evidence. There is no medical therapy consistently proven to 
improve clinical endpoints.186 Medium dose [15–20 mg/day] ursodeoxy-
cholic acid has been abandoned by most countries although an appro-
priately sized study to address potential benefit will most likely not be 
performed.200 High-dose ursodeoxycholic acid [28–30 mg/day] should be 
avoided in patients with PSC,201 and therapies such as anti-TNF or ved-
olizumab have not been appropriately studied. There is an urgent need for 
better therapies; several approaches [bile acid therapies, lymphocyte traf-
ficking blockade, antifibrotics and antibiotics] are under investigation.200
The proper treatment and early recognition of complications such as stric-
tures and cholangiocarcinoma are seminal to the management of patients with 
PSC. Brush cytology assessment for the detection of biliary dysplasia is neces-
sary when strictures are present. In the future, surrogate biomarker analysis 
and novel imaging modalities may allow differentiation between benign and 
malignant strictures in PSC.202 Endoscopic retrograde cholangiopancreatog-
raphy should be performed after antibiotic prophylaxis in patients with PSC, 
as this may reduce the risk of cholangitis, bacteraemia, and septicaemia, par-
ticularly in patients in whom biliary obstruction is not resolved after ERCP.203
In most centres, cholangiocarcinoma is a contraindication for 
liver transplantation except in highly selected cases of extra hepatic 
cholangiocarcinoma that also require neo-adjuvant chemo- and 
radiotherapy.204
Liver transplantation is the only therapy that can cure PSC. Outcomes 
are favourable, with 5-year survival rates close to 85%.205,206 PSC patients 
with end-stage liver disease should be assessed for liver transplantation 
according to standard guidelines. Patients with intractable pruritus and 
selected cases with recurrent, severe bacterial cholangitis can be referred 
for liver transplantation. The selection for, and timing of, transplanta-
tion in PSC patients is difficult, due to the unpredictable disease course 
and the risk of cholangiocarcinoma. Selected PSC patients with biliary 
brush cytology dysplasia appear to benefit from liver transplantation,207 
although this indication has not been widely implemented. There is a 
definite need for novel biomarkers that can improve the diagnostic accu-
racy of malignancy in biliary specimens.
7.1.3.1. Follow-up
PSC is associated with a 4-fold increased risk of colorectal neoplasia 
[dysplasia and cancer] in patients with associated IBD, both before and 
after liver transplantation.188,208 Colorectal neoplasia may appear soon 
after IBD and PSC have been diagnosed.209 Surveillance chromo-colo-
noscopy with targeted biopsies is recommended at diagnosis and every 1 
to 2 years thereafter.2,210 This programme should be continued after liver 
transplantation.
ECCO Statement 7D
No medical therapy has been shown to reduce time to 
liver transplantation, cholangiocarcinoma, or death in 
PSC or small-duct PSC [EL1]. Although ursodeoxycholic 
acid [15–20 mg/kg/d] improves serum liver tests [EL1], 
higher doses should be avoided [EL1]. Corticosteroids 
and/or immunosuppressants should be considered in 
patients with features of AIH [EL3]
ECCO Statement 7E
In PSC patients with clinical or radiological suspicion of 
significant strictures or cholangiocarcinoma, an ERC is 
recommended to diagnose strictures that may be ame-
nable to endoscopic dilatation [with or without stent-
ing] and for brush cytology specimen evaluation [EL2]. 
Prophylactic antibiotic therapy is recommended [EL1]
ECCO Statement 7F
PSC patients with end-stage liver disease or with debili-
tating symptoms of cholestasis should be considered for 
liver transplantation [EL1]. Liver transplantation may be 
considered in selected patients with cholangiocellular 
dysplasia on brush cytology [EL5]
ECCO Statement 7G
Surveillance colonoscopy in PSC patients with IBD is 
recommended every 1 to 2 years after diagnosis of PSC 
[EL1]. Chromo-endoscopy with targeted biopsies is the 
recommended surveillance strategy [EL2]. In PSC patients 
without evidence of IBD, colonoscopy is recommended 
every 5 years [EL5]
ECCO Statement 7H
There is no evidence-based follow-up regimen proven to 
detect biliary neoplasia earlier in PSC. Annual ultrasonog-
raphy to detect gallbladder mass lesions is recommended 
[EL4]. Additional imaging [MRI/MRC, CT, ERC] should be 
performed without delay if cholangiocarcinoma is sus-
pected [EL1]
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An algorithm for screening and surveying cholangiocarcinoma in 
PSC, including an annual measurement of serum carbohydrate antigen 
19-9 [CA 19-9] and abdominal ultrasound evaluation, has been pro-
posed211 but not validated. Gallbladder mass lesions are associated with 
a high risk [up to 56%] of malignancy in PSC patients.212 On this back-
ground, annual ultrasound to detect gallbladder polyps has been recom-
mended178 or considered,172 but not validated.
7.2. Non-PSC liver disease in IBD
7.2.1. Non-alcoholic fatty liver disease
The prevalence of non-alcoholic fatty liver disease ranges between 
1.5% to 55% in ulcerative colitis and 1.5% to 39.5% in Crohn’s dis-
ease [overall mean prevalence 23%].213 Risk factors are those of the 
metabolic syndrome and IBD-specific factors that include intraab-
dominal abcesses, fistulising disease, colitis severity, malnutrition, 
protein loss, and drugs [eg corticosteroids or methotrexate].214,215
7.2.2. Drug-induced liver injury
DILI affects many IBD patients,167 so laboratory monitoring of liver 
tests may be required every 1–3  months. DILI is uncommon and 
usually mild with 5-amino salicylic acid [5-ASA] drugs, but chronic 
hepatitis has been described.216 Increased aminotransferase levels are 
observed in approximately 10% of IBD patients started on metho-
trexate.217 Additional risk factors for liver disease [eg obesity and 
alcohol use] increase the risk of methotrexate-induced liver injury.218 
Withdrawal of methotrexate because of hepatotoxicity is unusual 
[5%]. Fibrosis may occur in patients treated with methotrexate, and 
can be assessed using serum biomarkers and transient elastography. 
It has been observed in 8.5% of patients treated with methotrex-
ate.219 The reported incidence of azathioprine- and 6-mercaptopu-
rine-hepatotoxicity varies among studies [3% to 15%].220 Most 
cases occur within the first few months of treatment.220,221 The hepa-
totoxic effect may be dose-dependent and usually manifests with 
aminotransferases and/or cholestatic enzyme elevation that return to 
normal after discontinuation of the drug.222 Up to 81% of patients 
who have liver toxicity while receiving azathioprine tolerate 6-mer-
captopurine.223,224 Thiopurines [including 6-thioguanine] may cause 
damage to the hepatic vascular endothelium, causing veno-occlusive 
disease, peliosis hepatis, and nodular regenerative hyperplasia. These 
should be suspected in the context of an elevated gamma GT and 
a thrombopenia, and confirmed by liver biopsy. Occasionally, aza-
thioprine and 6-mercaptopurine cause severe cholestatic jaundice 
that does not improve despite drug withdrawal. Several cases of anti 
TNF-induced AIH and cholestatic liver disease have been reported.225
7.2.3. Portal vein thrombosis
Portal vein thrombosis is a severe complication of IBD.226 It is 
more frequent in the postoperative setting.227 Measures to prevent 
thromboembolism during hospitalisation or IBD exacerbations are 
recommended.1,2 After diagnosis, appropriate assessments for both 
underlying [IBD-related] acquired prothrombotic conditions and 
inherited thrombophilia are indicated.228,229 Treatment with anticoag-
ulants in accordance with international guidelines is recommended.230
7.2.4. Hepatic amyloidosis
Secondary hepatic amyloidosis is a rare complication of IBD, with 
a reported frequency of 0.9% in CD and 0.07% in UC patients.231 
Longstanding active inflammation of the bowel may result in amy-
loid fibril deposition in hepatic blood vessels and sinusoids. There 
is no specific therapy, other than treatment of the underlying active 
IBD, although a direct effect of anti-TNF agents on serum amyloid 
protein levels has been reported.232
7.2.5. Granulomatous hepatitis
Granulomatous hepatitis in IBD may be an EIM of: CD, DILI [eg 
sulfasalazine]; an associated inflammatory disease such as primary 
biliary cirrhosis, sarcoidosis, Wegener’s disease;233,234,235 infection; or 
lymphoma.
7.2.6. Hepatic abscess
Hepatic abscesses are uncommon in IBD patients. However, an asso-
ciation with transmural inflammation has been suggested, including 
direct extension of intra-abdominal abscesses, portal pylephlebitis, 
or secondary to fistulising disease.236,237
7.3. Acute pancreatitis in IBD
7.3.1. Investigation and diagnostic criteria
The standardized incidence ratio for acute pancreatitis is approxi-
mately 4 in CD and 1.5–2 in UC.238,239,240 The clinical presentation 
and course of acute pancreatitis in IBD are similar to the general 
population.241,242,243 Diagnosis is based on the presence of at least 
two of three criteria: upper abdominal pain, elevated serum lipase, 
elevated amylase level [above three times the upper limit of normal], 
and consistent abdominal imaging. These criteria are sometimes dif-
ficult to apply in IBD, as abdominal pain due to pancreatitis can be 
difficult to differentiate from that caused by active IBD. In addition, 
an asymptomatic elevated lipase is found in 7% of IBD patients.244
7.3.2. Natural history and pathogenesis
Two IBD-specific forms of acute pancreatitis exist. The first is pre-
sumably related to shared pathogenic pathways and comprises 
autoimmune pancreatitis, idiopathic pancreatitis, granulomatous 
pancreatitis, and pancreatitis associated with PSC. The second is due 
to the management of IBD or due to its associated diseases [eg PSC], 
which includes biliary pancreatitis, drug-induced pancreatitis, pan-
creatitis secondary to duodenal CD; and post-ERCP or post-enteros-
copy pancreatitis.238,239,240
The most common causes are, by decreasing order of frequency, 
drugs [mostly thiopurines], gallstones, alcohol, and ERCP.241,243 
Autoimmune, IgG4-related pancreatitis has been described in 
IBD.245 Azathioprine- or 6-mercaptopurine-induced pancreatitis is 
dose independent. It occurs in approximately 4% of treated IBD 
patients.241,242,246 There is no evidence that monitoring lipase can 
ECCO Statement 7I
Apart from PSC, patients with IBD can develop non-alco-
holic fatty liver disease, drug-induced liver injury, hepatic 
and portal vein thrombosis, hepatic abscess, liver amyloi-
dosis, and granulomatous hepatitis [EL 3]
ECCO Statement 7J
Acute pancreatitis is usually associated with gallstone 
disease, alcohol intake, drug side effects [especially aza-
thioprine and 6-mercaptopurine], and duodenal CD [EL3]. 
Cases of granulomatous pancreatitis have been reported. 
Pain due to chronic pancreatitis is rare in IBD patients. In 
contrast, pancreatic exocrine insufficiency and pancreatic 
duct abnormalities are more frequent [EL3]
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predict disease risk, which typically occurs within the first 3 to 4 
weeks of treatment and has a mild course. The risk seems to be 
higher in CD.241,242 Patients who carry the HLA-DQA1*02:01-HLA-
DRB1*07:01 haplotype are more prone to develop pancreatitis after 
thiopurine administration.247 The risk of 5-ASA induced pancreatitis 
is much lower,216,248 similarly without evidence for a dose-response. 
Gallstones are an important cause, both within the general and IBD 
population. The risk of gallstones is increased in CD but not in UC.249
7.3.3. Treatment
Treatment of pancreatitis in IBD is in line with international 
guidelines.250
7.4. Chronic pancreatitis
Morphologically, chronic pancreatitis in IBD is characterised by the 
presence of pancreatic duct abnormalities, sometimes a pseudotu-
mour pattern; and, in most cases, absence of parenchymatous calci-
fication.251 The prevalence of pancreatic duct changes such as main 
duct obstruction, severe duct irregularity or dilatation, or ductal fill-
ing defects ,have been found to be 8% and 16% in patients with CD 
and UC, respectively, using ERCP and MRCP.252,253 In addition, 7% 
to 77% of patients with PSC have pancreatic duct changes.254,255,256 
Pancreatic autoantibodies directed against the exocrine pancreas 
are found in about one-third of CD and 4% of UC patients.257,258 
These autoantibodies are correlated with pancreatic exocrine 
insufficiency.259
8. Neurological disease
8.1. Investigation and diagnostic criteria
A case series260 identified and followed 33 IBD patients with periph-
eral neuropathy from a tertiary centre. Middle-aged males predomi-
nated, often with involvement of sensory fibres causing paraesthesia 
and pain. Demyelinating neuropathy was proportionally more com-
mon in women, with proximal and distal symmetrical weakness and 
distal sensory impairment/loss. All neuropathies [demyelinating, 
small-fibre sensory, large-fibre sensory, and sensorimotor] were pre-
sent equally in IBD patients. Peripheral neuropathy was related to 
disease activity in only about one-third of patients. Immunotherapy 
[often IV Ig] was associated with improvement in the majority. 
Anecdotal reports describe other types of neuropathy, including 
myositis, myasthenia gravis, and myelopathies.261,262
Neuropathies affecting the central nervous system comprise 
cranial neuropathies, with case reports describing visual loss due 
to optic neuritis,263,264 ophthalmoplegia affecting the lateral rectus 
muscle,265 and hearing loss.118,266,267 Demyelinating diseases have also 
been reported. For the latter, IBD patients have been described with 
asymptomatic central nervous system white-matter lesions,268,269,270 
epilepsy271,272,273,273 and multiple sclerosis.274,275,276,277 Recently, several 
cases of posterior reversible encephalopathy syndrome [PRES], an 
entity characterised by headache, seizures, visual disturbance, altered 
mental status, and vasogenic oedema on neuro-imaging, have been 
reported in CD patients who received infliximab.278,279,280 Vasculitis 
and Takayasu’s arteritis have been reported, as well as acute dis-
seminated encephalomyelitis.281 Central neuropathies have been 
described that are independent of disease activity and may precede 
the onset of IBD. Cerebral sinus venous thrombosis should be sus-
pected in patients with a severe headache during a flare of IBD, with 
or without neurological deficit or seizure.282
IBD-related peripheral neuropathy can be considered after well-
known risk factors have been excluded, such as vitamin and mineral 
deficiencies [in particular vitamins B12, D, E, red-cell folate, thiamine, 
and nicotinamide, and copper], hypothyroidism, monoclonal gam-
mapathies, hepatitis C infection [cryoglobulins], and diabetes mellitus. 
A  temporal association to predisposing medication [mostly metroni-
dazole, but also anti-TNF agents283; see Table 3] should lead to their 
discontinuation. Electromyography, nerve conduction studies, and MRI 
are often required. Central nervous system manifestations due to IBD 
are very rare and therefore a thromboembolic event should first be 
excluded when symptoms involving the central nervous system occur.284
8.2. Natural history and pathogenesis
Single centres report wide-ranging values for the prevalence of neu-
rological manifestations in IBD, from 3% to 39%,271,272,285,286 but 
their applicability is limited by small sample size and referral bias. 
A large, retrospective cohort association study using the UK General 
Practice Research Database estimated an odds ratio for developing 
multiple sclerosis, demyelination, or optic neuritis of 1.54 [95% CI, 
1.03–2.32] for CD and 1.75 [95% CI, 1.28–2.39] for UC, with a con-
trol prevalence of 2.7/1000.277 However, a University of Manitoba 
population-based case-control study analysing more than 8000 IBD 
cases did not reveal an association for neuropathy, multiple sclerosis, 
or myasthenia when applying stringent diagnostic criteria, except for 
an increased risk of multiple sclerosis in middle-aged men with UC 
(risk ratio [RR] 1.90; 95% CI, 1.19–3.03) that may have represented 
a chance finding.276 A retrospective, population-based cohort of 772 
IBD patients, recruited between 1940 and 2004 at the Mayo clinic, 
reported the cumulative incidence of peripheral neuropathy as 0.7% 
after 10 and 20 years, and 2.4% after 30 years of IBD,287 concluding 
that neuropathy is uncommon in IBD. There are insufficient publica-
tions to predict the natural history.
Several mechanisms of peripheral neuropathy have been 
described273 comprising malnutrition, malabsorption with vita-
min and micronutrient deficiencies, intercurrent infection (eg zos-
ter viruses, Epstein-Barr virus ]EBV], cytomegalovirus [CMV], and 
human immunodeficiency virus [HIV]), and iatrogenic causes [medi-
cation side effects, surgical trauma]. Mechanisms of central nervous 
system manifestations include thromboembolism and inflammation.
8.3. Treatment
Treatment requires avoiding exposure to implicated medication, 
treating comorbidities, and normalising vitamin levels. Since periph-
eral neuropathy is usually unrelated to IBD activity, treatment of the 
underlying bowel activity does not improve the neuropathy. There 
are no controlled trials to guide therapeutic recommendations.288 
ECCO Statement 8A
Peripheral neuropathy is very rarely associated with IBD 
[EL  3]. Treatable causes [eg vitamin and micronutrients 
deficiencies, metronidazole] need to be identified
ECCO Statement 8B
Central nervous system manifestations may be more 
common in IBD patients than in the general population 
[EL  4]. Causes to be considered include venous sinus 
thrombosis, stroke, and central demyelination. The latter 
may worsen with, and is a contraindication to, anti-TNF 
therapy [EL 4]
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Intravenous Ig260 and plasmaphereses have been successful in case 
series.289,290 Some lesions may be immune-mediated, therefore 
immunosuppressants have been recommended.291 Demyelination is 
a contraindication to the use of anti-TNF agents, which have been 
associated with demyelination,292 with a ‘possible’ or ‘probable’ 
causality as defined by the Naranjo score.283 Adverse drug reactions 
involving the neurological system are probably by far the most fre-
quent neurological manifestation in IBD patients. A  summary of 
these is shown in Table 3.
9. Cardiovascular manifestations of IBD
9.1. Investigations and diagnostic criteria
Two recent meta-analyses of cohort and case-control studies in 
Western populations report a modestly increased risk of arterial 
thromboembolism in IBD;293,294 particularly ischaemic heart disease, 
stroke, and mesenteric ischaemia.
The increased risk of ischaemic heart disease in IBD was con-
firmed by both meta-analyses (OR 1.19 [95% CI, 1.08–1.31])293 
and (RR 1.35 [95% CI, 1.19–1.52]),294 whereas the increased risk 
of cerebrovascular accident (OR 1.18 [95% CI, 1.09–1.27])293 and 
of mesenteric ischaemia (RR 3.46 [95% CI, 1.78–6.71])294 were 
each reported by one meta-analysis. No differences were observed 
between CD and UC.293,294
The meta-analysis by Fumery et al.294 analysed only two studies 
of non-hospitalised patients, comprising 8866 IBD patients, and one 
very large database of hospital admissions that may be subject to 
methodological defects. By comparison, the earlier meta-analysis293 
analysed five studies, comprising 98 240 IBD patients. Women pri-
marily accounted for the increased risk of cerebrovascular accident 
(OR 1.28 [95% CI, 1.17–1.41]) and ischaemic heart disease (OR 1.26 
[95% CI, 1.18–1.35]).293 There was a higher risk of cerebrovascular 
accident in young IBD patients [< 40–50  years old].293 Mesenteric 
ischaemia was addressed in one meta-analysis assessing only two 
studies.294 This occurred in approximately 1/10 000 patients admitted 
to hospital, with a pooled risk ratio of 3.46 [95% CI, 1.78–6.71].
There appears to be no increased risk of peripheral arterial 
disease, based on meta-analyses pooling data from two studies, 
including one large population-based study (OR 1.15 [95% CI, 
0.96–1.38])293 and (OR 0.78 [95% CI, 0.46–1.32]).294 The rate of 
peripheral vascular disease is low in IBD, affecting only 0.5% of 
patients.293
Studies have not demonstrated an increased cardiovascular mor-
tality in IBD, in contrast to rheumatoid arthritis. This is likely due to 
inadequate power in the context of falling mortality rates, relatively 
short-term follow-up, and low prevalence studies in predominantly 
youthful IBD cohorts.
The majority of studies assessing cardiovascular risk factors 
[hypertension, diabetes, dyslipidaemia, obesity, or the compos-
ite Framingham risk score] in IBD patients report a low preva-
lence.295,296,297,298 This could underestimate the risk in IBD patients 
who have chronic systemic inflammation leading to premature 
atherosclerosis. Recently an association between IBD activity and 
myocardial infarction, stroke, and cardiovascular death was demon-
strated in a Danish population-based study. However, the risk of car-
diovascular complications and mortality was similar to the general 
population in patients with quiescent disease.299 In detail, the relative 
risk was 1.49 [95% CI, 1.16–1.93] and 2.05 [95% CI, 1.58–2.65] 
for myocardial infarction, 1.53 [95% CI, 1.22–1.92] and 1.55 [95% 
CI, 1.18–2.04] for stroke, and 2.32 [95% CI, 2.01–2.68] and 2.50 
[95% CI, 2.14–2.92] for cardiovascular mortality during disease 
flares, or with persistent activity, respectively.
Clinical features, investigations and diagnostic criteria of cardio-
vascular events are similar in patients with and without IBD
9.2. Natural history and pathogenesis
The largest meta-analysis of cardiovascular mortality in IBD294 
identified 15 studies containing 69 383 patients and, concordant 
with previous meta-analyses,300,301,302,303 did not reveal increased 
mortality in comparison with the general population. However, a 
population-based study from Denmark299 and a nationwide register 
from Finland,304 neither included in the meta-analysis, have shown 
increased cardiovascular mortality in IBD during periods of inflam-
matory activity,299 and have shown that patients with UC, but not 
CD, have increased mortality for cardiovascular disease (RR 1.14 
[95% CI, 1.06–1.22]).304
Systemic inflammation predisposes to atherosclerosis and coro-
nary artery disease.305 This has been demonstrated in rheumatoid 
arthritis306,307 and in IBD.299 Raised CRP has been independently 
associated with coronary artery disease.308 Intima-media thickness, 
a surrogate of atherosclerosis, is increased in IBD.309 Premature 
Table 3. Neurological drug adverse events.
Drug Adverse events Prevalence/comments
Metronidazole PN390,391,392 21–39%
Sulfasalazine PN, myelitis, meningitis, GBS393 Associated with folate deficiency
Ciclosporin A Tremor, epilepsy, PN, central leukoencephalopathy, paraesthesia, 
ataxia, aphasia394,395
25% risk of neurological symptoms [at risk with 
low cholesterol, low Mg++, hypertension, previous 
seizure]
Anti-TNF Central demyelination292,396,397,398,399
Optic neuritis400,401,402,403,404,405
PN283,406
GBS407
Thalidomide PN408 25% of users
Natalizumab PML409 1/1000, due to JC virus
PML, progressive multifocal leukoencephalopathy; PN, peripheral neuropathy; GBS, Guillain-Barré syndrome; JC, John Cunningham.
ECCO Statement 9A
The risks of ischaemic heart disease, cerebrovascular accident, 
and mesenteric ischaemia are modestly increased in IBD [EL 2], 
particularly in women [EL 3]. Systemic inflammation predis-
poses to premature atherosclerosis [EL 3]. Cardiovascular mor-
tality has not been shown to be increased in IBD [EL 2]
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atherosclerosis in IBD patients occurs due to a combination of 
inflammation, endothelial dysfunction, calcification, and hyperco-
agulability.310,311,312 Hyperhomocysteinaemia, a well-established risk 
factor for arterial and venous thrombosis, is four times more preva-
lent in IBD than in the general population.313 Furthermore, hyper-
coagulability due to systemic inflammation contributes to earlier 
atherosclerosis and therefore an elevated risk of arterial thrombotic 
events.310 Impaired coagulation factors include: elevated factors V, 
VII, VIII, fibrinogen, and prothrombin fragments; lower plasma 
levels of thrombin inhibitors such as anti-thrombin III as well as 
abnormal fibrinolysis; and abnormal platelet activation evidenced 
by increased circulating platelet numbers and platelet-leukocyte 
aggregates. Finally, smoking is over-represented in CD patients and 
predisposes to atherosclerosis.
9.3. Treatment
It has been speculated that IBD treatment could reduce cardiovas-
cular risk by suppressing inflammatory activity.314 Recent Danish 
population-based studies299,315 analysed the effect of therapy upon 
cardiovascular complications. In one study, ischaemic heart disease 
was lower in patients using 5-aminosalicylic acids (RR 1.16 [95% 
CI, 1.06–1.26]) than non-users (RR 1.36 [95% CI, 1.22–1.51]); 
treatment with thiopurines and TNF-alpha antagonists was associ-
ated with less ischaemic heart disease, the lowest risk being observed 
in those treated with combination therapy.315 In the other study, 
myocardial infarction, cerebrovascular accident, and cardiovascu-
lar death did not occur in patients treated with anti-TNF agents, 
whereas the risk was comparable to the total IBD population in 
patients treated with immunosuppressants, although the value of 
this finding was limited by the small sample size.299 Patients should 
be advised to avoid known cardiovascular risk factors, including 
cigarette smoking.
10. Pulmonary manifestations of IBD
10.1. Investigation and diagnostic criteria
Bronchopulmonary disease is a rare EIM of IBD.316,317 The true 
prevalence is unknown. Pulmonary function tests are frequently 
abnormal in IBD, even in the absence of respiratory symptoms. 
Several studies report latent interstitial pulmonary involvement in 
20% to 55% of IBD patients. These abnormalities include bronchial 
hyper-responsiveness, ventilation defects, and sputum or bronchoal-
veolar lavage lymphocytosis, as well as histological and radiological 
abnormalities.318,319,320,321,322,323
Infections and adverse drug reactions frequently cause parenchy-
mal lung disease in IBD patients and should always be excluded. 
The presentation of other bronchopulmonary manifestations is pol-
ymorphic, as all segments of the respiratory tract can be affected. 
Respiratory symptoms in patients receiving corticosteroids, immu-
nomodulators, and/or anti-TNF therapy should not be ignored, 
because they may indicate the onset of a serious opportunistic 
infection.324
10.1.1. Drug-induced manifestations
The most common pulmonary manifestation of IBD is drug-induced 
lung disease, frequently attributed to 5-ASA or methotrexate. 
Salicylates [sulfasalazine, 5-ASA] induce different types of interstitial 
lung disease.316 The most common symptoms are dyspnoea, fever, chest 
pain, and cough. Peripheral eosinophilia is found in almost half the 
cases.316 Methotrexate may cause severe hypersensitivity pneumonitis 
or pulmonary fibrosis.325 Granulomatous inflammation compatible 
with sarcoidosis has been documented in patients receiving anti-TNF 
monoclonal antibodies.326 This paradoxical inflammation improves 
with cessation of the anti-TNF agent and/or steroid treatment.
10.1.2. Broncho-pulmonary manifestations specific to IBD
Bronchopulmonary involvement in IBD encompasses a wide range 
of manifestations.316,327,328,329,330,331,332 In most cases, IBD precedes the 
pulmonary manifestations. Different patterns of respiratory involve-
ment can be defined [Table 4].
The most common pattern is airway inflammation, involving the 
bronchial tree from glottis to small airways. Bronchiectasis is most 
commonly reported.316,330 The inflammatory lesions are similar to 
those observed in the digestive tract. Persistent airway inflammation 
can result in airway narrowing and expose patients to the risk of irre-
versible destruction of the airways, resulting in subglottic/tracheal 
strictures,329,333,334,335,336,337,338,339,340 chronic bronchitis, bronchiectasis, 
or bronchiolitis obliterans. These manifestations are more frequently 
observed after colonic surgery.329,341 Chronic bronchitis is diagnosed 
with cough and mucus expectoration for more than 3 months a year 
during 2 consecutive years, with a normal high resolution CT scan. 
Bronchiectasis is diagnosed by high resolution CT, with a bronchial 
calibre greater than the adjacent vessel. Bronchiolitis or small airway 
diseases are diagnosed by high resolution CT, with centrolobular micro-
nodules and a ‘tree in a bud’ aspect, with air trapping on the expiratory 
sequence.
Interstitial lung diseases are caused by infiltration of the alveolar 
air spaces or thickening of pulmonary interstitial structures. A  clas-
sification can be used to distinguish the different types of interstitial 
pneumonia.342 Granulomatous interstitial lung disease, mimicking 
parenchymal sarcoidosis, may be observed in CD patients. Many 
patients with CD and concomitant sarcoidosis have been reported in 
the literature, suggesting a link between the two diseases,316,330 which 
share susceptibility genes.343 Other types of interstitial pneumonia 
have been described in IBD patients. These include non-specific inter-
stitial pneumonia, usual interstitial pneumonia, organising pneumonia 
(formerly termed bronchiolitis obliterans with organising pneumonia 
[BOOP]), lymphocytic interstitial pneumonia, desquamative intersti-
tial pneumonia, eosinophilic interstitial pneumonia, and hypersensitiv-
ity interstitial pneumonia. In most patients the development of pul-
monary disease parallels that of the intestinal disease activity and/or 
other EIMs.332 The most common pattern of interstitial lung involve-
ment is organising pneumonia, which may also occur secondary to 
other inflammatory disorders such as rheumatoid arthritis. It is char-
acterised histologically by intraluminal plugs of connective tissue in 
the bronchioles that extend distally into adjacent alveolar ducts and 
alveoli. Pulmonary infiltrates with eosinophilia have been reported in 
ECCO Statement 10A
Different types of airway disease, involving different parts of 
the bronchial tree from the glottis to small airways, can occur 
as an extra-intestinal manifestation of IBD [EL4], most com-
monly the large airways [EL4]. There is an association between 
IBD and chronic obstructive pulmonary disease [EL3]
ECCO Statement 10B
Interstitial pneumonia associated with IBD has been 
described, the most common form being organising 
pneumonia [EL4]. Infections or medication [salicylates, 
methotrexate, thiopurines, anti-TNF] can cause parenchy-
mal lung disease
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IBD patients who did not receive salicylates. Diagnosis of these entities 
relies on clinical presentation, high resolution CT, and bronchoalveolar 
lavage, and may require lung biopsy. Other rare bronchopulmonary 
manifestations have been reported including pulmonary fistulae of 
ileal, colonic, or even oesophageal origin, necrotic nodules due to neu-
trophilic infiltrates, pulmonary vasculitis, and pleuritis.316,317,329
10.2. Natural history and pathogenesis
There is an association between IBD and chronic obstructive 
pulmonary disease, characterised by chronic inflammation of the 
airways. A population-based cohort study showed that patients 
with chronic obstructive pulmonary disease had a significantly 
higher risk of both UC (HR 1.83 [95% CI, 1.61–2.09]) and CD 
(HR 2.72 [95% CI, 2.33–3.18]), as compared with healthy con-
trols.344 The risk of CD among patients with chronic obstructive 
pulmonary disease was greater than the risk reported for smok-
ing alone. A  meta-analysis of population-based studies of mor-
tality in CD found a significant, increased risk of death from 
pulmonary cancer (summary measure of risk [SMR] 2.72 [95% 
CI, 1.35–5.45]), as well as chronic obstructive pulmonary disease 
(SMR 2.55 [95% CI, 1.19–5.47]).302 In another population-based 
study, CD and UC patients had an increased risks of asthma and 
bronchitis.276
Gastrointestinal and respiratory tracts share components of the 
common mucosal immune system.345 Hence, epithelial and mucosal 
immune defects associated with IBD may affect the respiratory tract. 
Trafficking of immune cells from inflamed intestinal tissue to the 
periphery and then to extra-intestinal mucosal surfaces may also be 
responsible for respiratory tract inflammation. Among first-degree 
relatives of chronic obstructive pulmonary disease patients, there 
is an overall increased risk of CD (HR 1.25 [95% CI, 1.09–1.43]) 
but not of UC (HR 1.09 [95% CI, 0.96–1.23]),344 suggesting that 
chronic obstructive pulmonary disease and IBD may share common 
inflammatory pathways, including variants of genes predisposing to 
both diseases.
10.3. Treatment
In all cases, drug-induced pulmonary disease must be excluded. 
In patients receiving salicylates or methotrexate, it is reasonable 
to consider the drug as a potential cause and withdraw it. Most 
of the respiratory changes associated with IBD respond to corti-
costeroids. The route of administration depends on the pattern of 
respiratory involvement. Inhaled corticosteroids [budesonide and 
beclomethasone] are particularly effective in large-airway involve-
ment and represent first-line treatment. Systemic corticosteroids are 
used in parenchymal involvement and in large-airway disease resist-
ant to inhaled corticosteroids. Ineffectiveness of inhaled corticos-
teroids may be due to limited diffusion in secretion-filled airways; 
nebulised corticosteroids can be used in these cases. Patients with 
steroid resistance or high-dose steroid-dependent refractory lung 
disease should be treated with immunomodulators and/or biologi-
cal therapy. Efficacy of anti-TNF therapy has been reported in lung 
disease associated with CD.346
11. Urogenital manifestations of IBD
The prevalence of renal insufficiency has been reported to be 2% in 
CD patients347 and as high as 15% in a series of inpatients with CD 
or UC.348 Risk factors for renal insufficiency were length of resected 
small bowel, duration of disease, age, and a history of renal stones. 
Patients with IBD, particularly those with CD, are prone to neph-
rolithiasis containing uric acid or calcium oxalate.349 Secondary 
amyloidosis [AA-type] is a rare but severe complication of IBD. 
Patients at risk of amyloidosis are male, with ileocolonic and/or 
perianal CD.350 Some patients have responded to infliximab.351,352 
Tubulo-interstitial nephritis, including granulomatous interstitial 
nephritis,353 has been reported as an EIM of IBD. Several cases of 
glomerulonephritis associated with IBD, including IgA nephrop-
athy, have been reported, suggesting that it could be an EIM of 
IBD.354
Sulfasalazine and 5-ASA may cause renal toxicity [glomerulo-
nephritis, nephrotic syndrome and, most importantly, interstitial 
nephritis]. Salicylates may cause either acute or chronic interstitial 
nephritis, independently of the dose administered.355 Renal impair-
ment may be isolated or associated with fever, eosinophilia, and 
rash. The injury is reversible, except when the diagnosis is delayed. 
Since the risk is higher during the first few months of treatment,356 
it is recommended to monitor renal function either every 4 weeks 
during the first 3 months or 3-monthly for the first year and then 
every year.349 Ciclosporin can cause acute renal failure due to 
afferent arteriolar constriction, resulting in decreased renal blood 
flow and glomerular filtration rate.357 Reduction or discontinua-
tion of ciclosporin usually improves renal function after 5–7 days. 
Ciclosporin may also cause chronic renal impairment [interstitial 
fibrosis, tubular nephropathy, and/or arteriolar injury] in up to 
20% of patients.349
Table 4. Respiratory manifestations associated with IBD—sites and patterns of involvement.
Anatomical site Pathology Symptoms/investigations
Larynx, glottis, trachea Inflammation and stenosis Stridor, hoarseness, cough
Bronchoscopy ± biopsy
Bronchi Chronic bronchitis [non-specific, granulomatous]
Bronchiectasis
Cough, sputum production
Bronchoscopy ± biopsy
High resolution CT scan
Bronchioles Granulomatous bronchiolitis
Diffuse pan-bronchiolitis
Dyspnoea, cough, bronchorrhoea, wheezing
Bronchoscopy ± biopsy
High resolution CT scan
Parenchymal tissues Usual interstitial pneumonia
Organising pneumonia
Lymphocytic interstitial pneumonia
Desquamative interstitial pneumonia
Eosinophilic interstitial pneumonia
Granulomatous interstitial lung disease
Dyspnoea, fever, acute respiratory failure, chest 
pain
High resolution CT scan
Lung biopsy
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Penile and scrotal swelling have been reported as metastatic 
[granulomatous] CD manifestations.358 Metastatic, granuloma-
tous, vulvar involvement [induration and/or swelling] has also been 
reported and may reveal CD.359
12. Coagulopathy in IBD
12.1. Investigation and diagnostic criteria
IBD patients have a higher risk of VTE than healthy controls. The 
most common forms of VTE are deep-vein thrombosis [DVT] and 
pulmonary embolism. A  recent meta-analysis360 of 11 case-control 
and cohort studies found the relative risk for DVT and pulmonary 
embolism among IBD patients to be 2.20 [95% CI, 1.83–2.65]. 
A separate meta-analysis of three large population-based, retrospec-
tive cohort studies revealed a 2.85-fold increased risk.361 Another 
meta-analysis of 33 observational studies reported an increased risk 
of DVT (RR, 2.42 [95% CI, 1.78–3.30]) and pulmonary embolism 
(RR, 2.53 [95% CI, 1.95–3.28]).294 In a series of 10 431 IBD patients 
who underwent surgery, VTE occurred in 1.4% of CD and 3.3% of 
UC patients.362
VTE is associated with disease activity; therefore patients may 
have signs of active and complex IBD. Although the risk of VTE 
is greater during hospitalisation,363,364 the majority of VTE events 
occur in outpatients who have risk factors [recent hospitalisation 
or surgery, active disease].365,366 VTEs often manifest with non-
specific symptoms and their presence should be considered in all 
patients.
VTE is diagnosed by standard protocols in patients with IBD, 
while trying to minimise radiation exposure.367 The most widely 
used procedures are ultrasound for DVT and the ventilation-
perfusion scan or CT pulmonary angiography for pulmonary 
embolism.
12.2. Natural history and pathogenesis
VTE complicating IBD is associated with longer hospitalisation 
[11.7 vs 6.1 days].363 IBD-related mortality is increased when VTE 
occurs [17.0 vs 4.2 per 1000 hospitalisations for CD; 37.4 vs 9.9 
per 1000 hospitalisations for UC; p  <  0.0001].363 Recurrent VTE 
is increased in IBD patients, half of whom have active disease at 
recurrence368; 33.4% [95% CI, 21.8%–45.0%] recur within 5 years 
in IBD patients who had an unprovoked first VTE, compared with 
21.7% [95% CI, 18.8%–24.6%] among patients without IBD 
[p = 0.01] (relative risk 2.5 [95% CI, 1.4–4.2]; p = 0.001]).
Known inherited risk factors for VTE (factor V Leiden [FVL], fac-
tor II prothrombin, G20210A), methylenetetrahydrofolate reductase 
gene mutation [MTHFR, 6777T], plasminogen activator inhibitor 
type 1 [PAI-1] gene mutation, and factor XIII [val34leu]] occur with 
a similar frequency in IBD and the general population.369,370 Excess 
VTE in IBD patients is the result of interactions between acquired 
and inherited risk factors. The most important acquired risk factors 
are disease activity [relative incidence of VTE during disease flares 
compared with remission is 4.5], hospitalisation [6-fold higher risk 
in hospitalised compared with non-hospitalised patients], colonic 
disease ,and recent surgery [the prevalence of VTE after surgery is 
2.3 %].371 A large case-control study364 is illustrative; the relative risk 
of VTE was 4-fold for all IBD patients [2.6/1000 patient-years], with 
a 15-fold relative risk during a flare in IBD [9 episodes/1000 patient-
years]. The absolute risk increased to 37.5/1000 patient-years in 
those hospitalised with a flare. Fistulising or stenosing disease are 
also independently associated with greater risk.363 Prolonged immo-
bilisation, central venous catheters, corticosteroids,372 oral con-
traceptives, and cigarette smoking have also been reported as risk 
factors. Hyperhomocysteinaemia, a potential risk factor for VTE, 
can be secondary to folate and vitamin B12 deficiencies that are 
observed in some IBD patients. Young IBD patients with VTE usu-
ally have at least one of these risk factors. Treatment with anti-TNF 
decreases coagulation biomarkers and activates fibrinolysis,371 which 
could reduce risk of VTE. Other chronic inflammatory diseases [eg. 
rheumatoid arthritis] or other chronic bowel diseases [eg coeliac dis-
ease] do not confer an excess risk of VTE.373 Perioperative independ-
ent risk factors have been reported as preoperative anaemia (OR 
1.5 [95% CI, 1.1–2.0]), use of corticosteroids (OR 2.17 [95% CI, 
1.7–2.8]), malnutrition (OR 1.41 [95% CI, 1.1–1.9]), and anaesthe-
sia time > 231 min (OR 1.96 [95% CI, 1.5–2.6]).362
12.3. Treatment
The treatment of VTE in IBD patients follows the same protocols 
as for non-IBD patients. Although low-molecular-weight heparin 
is most commonly used initially, low-dose unfractionated heparin 
or fondaparinux are acceptable alternatives. Long-term treatment 
usually comprises vitamin K antagonists [acenocoumarol, warfarin, 
fluindione, phenprocoumone] or the new, non-vitamin K antagonist 
oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and 
edoxaban. There is no evidence on their use in the setting of IBD, but 
data from the general population have shown that apixaban 2.5 mg 
twice daily is associated with less bleeding episodes than either 
rivaroxaban 20 mg daily or dabigatran 150 mg twice daily.374 The 
duration of treatment depends on the balance between the risk of 
recurrence [previous history, risk factors] and the risk of treatment-
induced bleeding.371 Clinicians should be aware that thiopurines can 
reduce the effect of warfarin.
Indefinite anticoagulant therapy can be discussed with IBD 
patients who present with a VTE episode while in clinical remission 
without another provoking factor. Thromboprophylaxis should be 
considered for all inpatients with IBD. VTE occurs in about 2% of 
patients following hospitalisation for IBD, with incidences at 30, 60, 
90, and 180 days of 3.7, 4.1, 5.4, and 9.4 per 1000 person-days, 
respectively.375 Pharmacological thromboprophylaxis during the 
index hospitalisation is associated with a significantly lower risk of 
post-hospitalisation VTE (HR 0.46 [95% CI, 0.22–0.97]).375 There 
is no evidence for prophylaxis of active disease in outpatients with 
IBD or for those flying, although high altitude has been associated 
with flares in disease.376 IBD patients undergoing surgery should also 
receive anticoagulant thromboprophylaxis during hospitalisation. 
ECCO Statement 12A
Venous thromboembolism [VTE] is related to IBD activity 
[EL  2]. Prophylaxis is recommended for all IBD patients 
admitted to hospital, and should be considered following 
discharge from hospital and after recent surgery, and in 
outpatients with active disease [EL 3]
ECCO Statement 12B
The risk of VTE is at least 2-fold higher in IBD than in 
the general population and therefore the threshold to 
perform investigations is lower, especially in those with 
active disease [EL3]. Treatment should follow established 
antithrombotic therapy guidelines
ECCO Guidelines/Consensus Paper 15
 by guest on February 17, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
IBD-related bowel surgery confers an increased risk of VTE after 
surgery, more in UC than CD [3.3% vs 1.4%, p < 0.001].362
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Disclaimer Text
The ECCO Consensus Guidelines are based on an international Consensus 
process. Any treatment decisions are a matter for the individual clinician 
and should not be based exclusively on the content of the ECCO Consensus 
Guidelines. The European Crohn´s and Colitis Organisation and/or any of 
its staff members and/or any consensus contributor may not be held lia-
ble for any information published in good faith in the ECCO Consensus 
Guidelines.
Conflict of Interest
ECCO has diligently maintained a disclosure policy of potential conflicts of 
interests [CoI]. The conflict of interest declaration is based on a form used by 
the International Committee of Medical Journal Editors [ICMJE]. The CoI 
statement is not only stored at the ECCO Office and the editorial office of JCC 
but also open to public scrutiny on the ECCO website [https://www.ecco-ibd.
eu/about-ecco/ecco-disclosures.html] providing a comprehensive overview of 
potential conflicts of interest of authors.
Acknowledgments
We are particularly grateful to Julia Gabriel and Nicole Eichinger from the 
ECCO office for their substantial contribution to coordinating and assimilat-
ing the Consensus. We are grateful to Margaret Callan, Axel Dignass, Gionata 
Fiorino, Christian Maaser, and members of the ECCO Governing Board [SV, 
GM, ST, FB, LP-B, JP] for quality control. We are grateful to all those who 
expressed an interest in and commitment to the ECCO Consensus process 
[described at www.ecco-ibd.eu].
References
For full References, please see the Supplementary Data at ECCO-JCC online.
16 M. Harbord et al.
 by guest on February 17, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
